このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Innate Pharma マネジメント

マネジメント基準チェック /44

Innate Pharma'sの CEO はHerve Braillyで、 Jan1999年に任命され、の在任期間は 25.58年です。は、会社の株式の0.91%を直接所有しており、その価値は€ 1.52M 。経営陣と取締役会の平均在任期間はそれぞれ4.5年と5.8年です。

主要情報

Herve Brailly

最高経営責任者

€100.0k

報酬総額

CEO給与比率	n/a
CEO在任期間	25.7yrs
CEOの所有権	0.9%
経営陣の平均在職期間	4.5yrs
取締役会の平均在任期間	5.8yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Herve Brailly (63 yo)

25.7yrs

在職期間

€100,000

報酬

Dr. Herve Brailly, Ph.D. Co-Founded Innate Pharma S.A in 1999 and served as its Chairman of Supervisory Board since December 31, 2016 until January 1, 2024 and serves as its Interim CEO and Chairman of the...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Herve Brailly	Co-Founder	25.7yrs	€100.00k	0.91% € 1.5m
Yannis Morel	Executive VP	9.3yrs	€599.92k	0.24% € 390.3k
François Romagné	Founder	no data	データなし	データなし
Eric Vivier	Founder	6.7yrs	データなし	0.26% € 422.6k
Marc Bonneville	Founder	no data	データなし	データなし
Jean Fournié	Founder	no data	データなし	データなし
Alessandro Moretta	Founder	no data	データなし	データなし
Frederic Lombard	Senior VP & CFO	3.4yrs	データなし	0.014% € 22.8k
Sonia Quaratino	Executive VP	less than a year	データなし	データなし
Arvind Sood	Executive VP	less than a year	データなし	データなし
Henry Wheeler	Vice President of Investor Relations & Communication	1.7yrs	データなし	0.0039% € 6.4k
Odile Belzunce	Vice President of Compliance & Operations	5.7yrs	データなし	0.077% € 125.1k

4.5yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: IDDAの経営陣は経験豊富であると考えられます ( 4.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Mario Sznol	Strategic Advisory Board Member	5.8yrs	データなし	データなし
Olivier Martinez	Member of Supervisory Board	no data	データなし	データなし
Ruslan Medzhitov	Strategic Advisory Board Member	5.8yrs	データなし	データなし
Gilles Brisson	Independent Member of Supervisory Board	17.3yrs	€29.00k	0.090% € 146.8k
Jean-Yves Blay	Independent Member of Supervisory Board	6.8yrs	€29.00k	0.000060% € 97.6
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	15.3yrs	€42.00k	0.031% € 50.5k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	4.3yrs	€60.00k	0.0012% € 2.0k
Miriam Merad	Chairman of Strategic Advisory Board	5.8yrs	データなし	データなし
Veronique Chabernaud	Independent Member of Supervisory Board	9.4yrs	€48.00k	0.00082% € 1.3k
Sebastian Amigorena	Strategic Advisory Board Member	5.8yrs	データなし	データなし
Aurelien Marabelle	Strategic Advisory Board Member	5.8yrs	データなし	データなし
Tanguy Seiwert	Strategic Advisory Board Member	5.8yrs	データなし	データなし

5.8yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: IDDAの取締役会は経験豊富であると考えられます ( 5.8年の平均在任期間)。

Innate Pharma マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Recent updates

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44